GlycoPEGylated factor IX: A new step forward

Research output: Contribution to journalArticle

Abstract

In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.

Original languageEnglish
Pages (from-to)3836-3837
Number of pages2
JournalBlood
Volume124
Issue number26
DOIs
Publication statusPublished - Dec 18 2014

Fingerprint

Hemophilia B
Factor IX
Blood
Hemorrhage
Molecules
Therapeutics
nonacog beta pegol

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

GlycoPEGylated factor IX : A new step forward. / Mancuso, Maria Elisa.

In: Blood, Vol. 124, No. 26, 18.12.2014, p. 3836-3837.

Research output: Contribution to journalArticle

Mancuso, Maria Elisa. / GlycoPEGylated factor IX : A new step forward. In: Blood. 2014 ; Vol. 124, No. 26. pp. 3836-3837.
@article{600d72eb88fe4fbea9cef666eb45dc8a,
title = "GlycoPEGylated factor IX: A new step forward",
abstract = "In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.",
author = "Mancuso, {Maria Elisa}",
year = "2014",
month = "12",
day = "18",
doi = "10.1182/blood-2014-10-604983",
language = "English",
volume = "124",
pages = "3836--3837",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - GlycoPEGylated factor IX

T2 - A new step forward

AU - Mancuso, Maria Elisa

PY - 2014/12/18

Y1 - 2014/12/18

N2 - In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.

AB - In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.

UR - http://www.scopus.com/inward/record.url?scp=84919493189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919493189&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-10-604983

DO - 10.1182/blood-2014-10-604983

M3 - Article

C2 - 25525079

AN - SCOPUS:84919493189

VL - 124

SP - 3836

EP - 3837

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -